Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ida Paris

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
European Journal of Clinical Pharmacology|November 20, 2016
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant CapecitabineMichela Roberto, Adriana Romiti, Andrea Botticelli, et al.
Current Oncology Reports|February 24, 2024
An Integrated Care Approach to Improve Well-Being in Breast Cancer PatientsAlessandra Fabi, Alessandro Rossi, Edoardo Mocini, et al.
Journal of Personalized Medicine|August 27, 2021
Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-AnalysisAlessia Romito, Sonia Bove, Ilaria Romito, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 20, 2026
Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancerAlessandra Fabi, Elena Giordani, Elena Ricciardi, et al.
Endocrine|May 1, 2026
Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practiceSabrina Chiloiro, Maria Grazia Maratta, Simone Antonio De Sanctis, et al.
Clinical Breast Cancer|August 12, 2020
Pregnancy-Associated Breast Cancer: A Multidisciplinary ApproachIda Paris, Danilo Di Giorgio, Luisa Carbognin, et al.
Clinical Breast Cancer|March 28, 2025
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective StudyGiovanna Garufi, Luca Mastrantoni, Noemi Maliziola, et al.
Scientific Reports|July 24, 2023
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving OlaparibFrancesco Schettini, Maria Valeria De Bonis, Carla Strina, et al.
BMC Cancer|March 20, 2020
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II studyRoberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, et al.
Reviews in Endocrine & Metabolic Disorders|May 29, 2026
Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature reviewSabrina Chiloiro, Simone Antonio De Sanctis, Bianca Parente, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
European Journal of Clinical Pharmacology|November 20, 2016
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant CapecitabineMichela Roberto, Adriana Romiti, Andrea Botticelli, et al.
Current Oncology Reports|February 24, 2024
An Integrated Care Approach to Improve Well-Being in Breast Cancer PatientsAlessandra Fabi, Alessandro Rossi, Edoardo Mocini, et al.
Journal of Personalized Medicine|August 27, 2021
Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-AnalysisAlessia Romito, Sonia Bove, Ilaria Romito, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 20, 2026
Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancerAlessandra Fabi, Elena Giordani, Elena Ricciardi, et al.
Endocrine|May 1, 2026
Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practiceSabrina Chiloiro, Maria Grazia Maratta, Simone Antonio De Sanctis, et al.
Clinical Breast Cancer|August 12, 2020
Pregnancy-Associated Breast Cancer: A Multidisciplinary ApproachIda Paris, Danilo Di Giorgio, Luisa Carbognin, et al.
Clinical Breast Cancer|March 28, 2025
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective StudyGiovanna Garufi, Luca Mastrantoni, Noemi Maliziola, et al.
Scientific Reports|July 24, 2023
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving OlaparibFrancesco Schettini, Maria Valeria De Bonis, Carla Strina, et al.
BMC Cancer|March 20, 2020
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II studyRoberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, et al.
Reviews in Endocrine & Metabolic Disorders|May 29, 2026
Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature reviewSabrina Chiloiro, Simone Antonio De Sanctis, Bianca Parente, et al.
Pageof 10